Skip to main content
Daniel Tenen, MD, Oncology, Boston, MA

Daniel G Tenen MD


Professor of Medicine, Beth Israel Deaconess Medical Center

Join to view full profile
  • Beth Israel Medical Center330 Brookline AveBoston, MA 02215

  • Phone+1 617-667-5561

Dr. Tenen is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1982 - 1984
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1975 - 1977
  • Harvard Medical School
    Harvard Medical SchoolClass of 1975

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1977 - Present
  • MA State Medical License
    MA State Medical License 1976 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • _-Catenin-Tcf/Lef Signaling Promotes Steady State and Emergency Granulopoiesis through G-CSF Receptor Upregulation
    Daniel G. Tenen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Long Noncoding RNA Loup Interacts with Runx1 and Regulates Long-Range Transcription of PU.1 in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Mutant p53 Drives Clonal Hematopoiesis Through Modulating Epigenetic Pathway
    Mutant p53 Drives Clonal Hematopoiesis Through Modulating Epigenetic PathwayDecember 11th, 2019

Grant Support

  • Molecular Biology Of Myeloid DifferentiationNational Heart, Lung, And Blood Institute2012
  • Oncogenesis And Myeloid Transcription Factors In AMLNational Cancer Institute2008–2012
  • Hematopoietic Stem Cell CommitmentNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
  • Targeting Leukemic Stem CellsNational Cancer Institute2008–2011
  • Distinct Acute Myeloid Leukemia Subclasses With Cebpa MutationsNational Cancer Institute2007–2011

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: